Generian Pharmaceuticals, Inc.
Generian Pharmaceuticals is a preclinical biotechnology company focused on developing novel, orally available small molecule therapeutics for diseases with high unmet need, especially in areas dominated by biologics. They aim to address the shortcomings of biologics by increasing convenience, access, and reducing costs through small molecule drugs. The company leverages a proprietary platform to advance a pipeline of first-in-class drug candidates that modulate target protein structure and function, with programs for both validated and novel targets, including collaborations with Astellas and Mitobridge.
Industries
Nr. of Employees
small (1-50)
Generian Pharmaceuticals, Inc.
Products
Preclinical small-molecule pipeline (FcRn inhibitors; transcription factor stabilizers/degraders)
A pipeline of orally bioavailable small-molecule programs including functional inhibitors of FcRn and programs that stabilize or degrade transcription factors; candidates are advanced through preclinical assays using cell-based binding screens and high-content phenotypic validation.
Preclinical small-molecule pipeline (FcRn inhibitors; transcription factor stabilizers/degraders)
A pipeline of orally bioavailable small-molecule programs including functional inhibitors of FcRn and programs that stabilize or degrade transcription factors; candidates are advanced through preclinical assays using cell-based binding screens and high-content phenotypic validation.
Services
Joint research and preclinical development agreements to discover novel small molecules for difficult-to-drug targets; collaborators take responsibility for clinical development, manufacturing, and commercialization under license terms.
Joint research and preclinical development agreements to discover novel small molecules for difficult-to-drug targets; collaborators take responsibility for clinical development, manufacturing, and commercialization under license terms.
Expertise Areas
- Small-molecule drug discovery
- Targeted protein modulation (stabilization, degradation, activation)
- Cell-based screening and phenotypic assays
- Preclinical candidate progression and lead optimization
Key Technologies
- Cell-based screening in native cellular context
- High-content phenotypic screening
- Small-molecule hit discovery
- Target engagement and functional cellular assays
News & Updates
Generian Pharmaceuticals announced that CEO Hank Safferstein will host investor meetings at the Cowen Healthcare Conference in Boston, MA, on March 7, 2023.
Generian announced that it has achieved the first research milestones for two programs under its collaboration with Mitobridge, focusing on transcription factors. The milestone payments are based on the identification of hit compounds impacting the stability and activity of these transcription factors.
Generian Pharmaceuticals is a preclinical biotech focused on developing small molecule therapeutics for high unmet need diseases, especially in biologics-dominated areas.
Generian Pharmaceuticals announced that CEO Hank Safferstein will host investor meetings at the Cowen Healthcare Conference in Boston, MA, on March 7, 2023.
Generian announced that it has achieved the first research milestones for two programs under its collaboration with Mitobridge, focusing on transcription factors. The milestone payments are based on the identification of hit compounds impacting the stability and activity of these transcription factors.
Generian Pharmaceuticals is a preclinical biotech focused on developing small molecule therapeutics for high unmet need diseases, especially in biologics-dominated areas.